Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Biomedical engineers at Duke University developed a method to overcome limitations of gene-targeted cancer drugs by combining CRISPR/Cas9 targeting with sustained release drug delivery. This strategy effectively addressed potency, elimination, and resistance issues, demonstrating improved efficacy in mice with colorectal cancers.
Researchers at The Institute of Cancer Research have discovered the three-dimensional structure and function of the 'mix n match' protein DHX8, which helps control a process linked to cancer progression and drug resistance. This study opens up a potentially exciting new way to tackle drug-resistant cancers.
A new simulation software aims to enhance process knowledge and speed up biopharmaceutical manufacturing. Christian Witz's software shortens simulation times from months to hours, enabling more efficient troubleshooting and insights into processes.
A new study reveals that many cancer drug candidates fail in clinical trials due to off-target effects, rather than targeting essential molecular mechanisms. This unexpected finding challenges over 180 previous reports on the importance of specific proteins for cancer cell survival.
Researchers at Cold Spring Harbor Laboratory identified 10 cancer drugs that don't work as expected, revealing an off-target effect. The discovery highlights the need for more accurate mechanism of action understanding in personalized medicine.
New studies show that KRAS gene mutations, common in colorectal and other cancers, vary in disease severity depending on the specific mutation and tissue location. The findings suggest that precision medicine approaches must be tailored to individual mutant forms of KRAS.
Researchers at Yale Cancer Center have identified a key metabolic pathway that enables cancer cells to adapt to their microenvironment and respond to nutrient availability. The study suggests that targeting this pathway with drugs may help treat various forms of cancer by preventing cancer cells from growing in nutrient-rich environments.
A pilot study under the Lung Cancer Master Protocol (Lung-MAP) found that most cancer patients lack a clear understanding of their genomic test results. The study revealed serious knowledge gaps about the potential uses of gene sequencing results, with only 86% correctly knowing their test results would select their treatment regimen.
Scientists at Scripps Research Institute have developed a new method for creating hindered ethers, which are integral to many drugs and commercial products. The new method uses electrochemistry and has improved production yield and reduced expense compared to traditional methods.
A clinical study comparing liquid and tissue biopsies finds multiple resistance mechanisms in individual patients, which could explain why targeted therapies often fail. The results suggest possible molecular mechanisms underlying drug resistance, pointing the way to new and more personalized therapeutics.
Researchers at Cold Spring Harbor Laboratory have discovered a way to tackle the development of resistance in pancreatic cancer by targeting the ERBB signaling pathway. This approach has shown promise in shrinking pancreatic tumors in mice, providing a potential avenue for overcoming resistance and improving treatment outcomes.
The LIBRETTO-001 trial showed that selpercatinib achieved high response rates of up to 68% in patients with RET fusion-positive non-small cell lung cancer. The median duration of response was also notable at 20.3 months, with an intracranial objective response rate of 91%.
Gold-based molecules have shown to be up to 24 times more effective at killing cancer cells than cisplatin and inhibit tumour growth by up to 46.9%. They also target an enzyme linked with cancer progression and have anti-inflammatory properties.
A novel swallowable balloon device has been cleared by the FDA for clinical use, allowing for early detection of Barrett's esophagus and reducing the risk of esophageal adenocarcinoma. The test is more than 90% sensitive and non-invasive, making it a promising tool for screening and prevention.
The pending Altria-Juul deal could lead to increased e-cigarette use or less cigarette use, depending on regulations and policies. Georgetown University professor David Levy explores the motivations behind the $12.8 billion purchase and its potential impact on public health.
Scientists have identified a cellular pathway that allows acute myeloid leukemia cells to evade the effects of drugs. They then engineered a compound that targets this pathway, blocking a mutant protein and halting the cancer cells' ability to sidestep the compound's effects.
The USPSTF recommends medications like tamoxifen, raloxifene, or aromatase inhibitors to reduce breast cancer risk in asymptomatic women over 35 with increased risk but low adverse effects risk. The Task Force advises against routine use for women not at high breast cancer risk.
A new study reveals a shift in obesity-associated cancers towards younger individuals, with significant increases in certain types of cancers among non-Hispanic Black and Hispanic women and men. The study found that the number of cases of these cancers increased by 25% to 400% in specific populations between 2000 and 2016.
A large international study found that cardiovascular disease (CVD) remains the leading cause of death worldwide, but its share has declined in high-income countries where cancer deaths have become more frequent. CVD risk factors are highest in rich countries, yet mortality rates are lower, suggesting other factors may be at play.
Researchers at Imperial College London found that hormone treatments can induce a dormant state in breast cancer cells, known as 'sleeper cells'. This could provide clues to why some cancers become resistant to treatment and may lead to new ways of preventing recurrence. Further research is needed to unlock the secrets of these cells.
Researchers identify CDK7 as a key player in prostate cancer growth and development, offering new treatment hope for metastatic castration-resistant prostate cancer (CRPC). Turning off CDK7 leads to the death of cancer cells, with limited off-target effects on healthy cells.
Researchers identified a drug combination that significantly extends patient survival in lung transplant recipients, offering a potential solution to the median survival rate of less than six years after transplantation. Sirolimus plus tacrolimus was associated with a better median survival than MMF plus tacrolimus.
Researchers have developed a hydrogel-based carrier that can deliver siRNAs directly to tumors, overcoming the challenge of rapid degradation and limited cellular entry. This innovative technology has the potential to improve the effectiveness of siRNA-based cancer treatments and enable more efficient delivery of biologics.
Researchers identified a molecule called DCAF15 that makes cancer cells more susceptible to natural killer cells. Blocking this molecule could lead to better survival rates for patients with acute myeloid leukemia.
A new drug, TAK-228, has demonstrated effectiveness in treating metastatic bladder cancer, slowing tumor growth and progression. The study found that four of seven patients showed a positive response to the treatment.
Oncologists suggest using nab-paclitaxel instead of paclitaxel prior to surgery for high-risk breast cancer patients, potentially improving long-term outcomes and reducing disease recurrence. This approach may be particularly beneficial for women with hormone receptor positive, HER-2 negative breast cancer.
Researchers at Flinders University have isolated a compound from the Australian white rock sea snail with antibacterial and anti-inflammatory properties, as well as important anti-cancer effects. The compound, part of the indole class, shows promise for preventing colon cancer tumor formation.
A recent study found that primary care physicians recommend health promotion to at least some cancer survivors, but oncologists and specialists rarely do. Cancer survivors face increased risks of cardiovascular disease if they don't adopt healthy lifestyles.
Researchers discovered an antibody drug that can destroy immune cells surrounding solid tumours, allowing T-cells to attack and kill cancer cells more effectively. The approach could improve treatments for various types of cancer, including CAR-T therapy.
The National Institute on Minority Health and Health Disparities has funded 11 research centers in minority institutions to foster the next generation of researchers and address health disparities. The centers will focus on diseases disproportionately affecting minority populations, including cancer, cardiometabolic diseases, and HIV/A...
Researchers identified a unique way to disrupt cellular process contributing to Diffuse Intrinsic Pontine Gliomas (DIPG). A vulnerability in the metabolic process for creating NAD was found, allowing for potential targeting of cancer cells with PPM1D mutation.
Researchers compared three frontline breast cancer drugs and found significant differences in their biological activity. Abemaciclib was shown to be more effective than other drugs at high doses, affecting proteins beyond CDK4/6, suggesting it may work differently for patients who don't respond to other treatments.
A clinical trial discovered that selinexor, a novel therapy, effectively knocked down bone marrow cancer in over a quarter of patients, including two who achieved complete remission. The treatment showed promise for patients resistant to multiple therapies and offered new hope for those with limited treatment options.
Researchers at CeMM Research Center have identified new targets for treating BAF mutant cancers by analyzing the effects of single subunit loss on chromatin accessibility and transcription. The study reveals that aberrant functions of remaining complexes may confer cancer-promoting properties, making them potentially druggable.
Researchers discovered a three-drug combination that sensitizes cancer cells to treatment, overcoming cross-therapy resistance. The approach involves time-sensitive administration of glucose-6-phosphate dehydrogenase inhibitors alongside other drugs.
Research found raised risks of blood clots, cardiomyopathy, and heart failure among cancer survivors, particularly those treated with chemotherapy. Long-term cardiovascular risks were elevated for over five years after diagnosis.
Researchers found that abemaciclib, a chemotherapeutic agent effective in breast cancer, has synergy when combined with HuR and YAP1 inhibitors to inhibit cell growth. The study suggests new targets for improving the efficacy of this drug and overcoming drug resistance in pancreatic cancer.
Researchers found that tumor cells depleted of ARID1A become highly sensitive to PARP inhibitor drugs after radiation treatment. This discovery could advance efforts to treat cancers resistant to current standard treatments.
A phase I trial is evaluating the combination of fecal transplants and immunotherapy for melanoma, with preliminary research suggesting a potential link between the human microbiome and treatment outcomes. Researchers aim to improve responses in 40-50% of patients treated with immunotherapy.
A recent study found that fewer than eight per cent of cancer drug trials included participation from all four major races in the US between 2008 and 2018. Black and Hispanic patients were particularly underrepresented, with rates of 22 per cent and 44 per cent respectively.
The observational study found significant changes in age distribution between obesity-associated and nonobesity-associated cancer cases over the 16-year period. The analysis revealed notable sex and racial disparities, with certain populations experiencing a higher risk of developing obesity-associated cancers at younger ages.
Researchers have identified a combination of treatments that may be more powerful than current therapy alone for children with Ewing sarcoma. The new approach combines FAK inhibitors with aurora kinase B targets to kill cancer cells and inhibit tumor progression.
Researchers at UCLA have developed a nanoscale capsule that breaks through the blood-brain barrier, allowing it to reach and treat cancer that has spread to the central nervous system. In mouse studies, this capsule delivered cancer-fighting drugs effectively eliminating B-cell lymphoma tumors.
A phase 1 clinical trial found that combining AZD1775, a Wee1 inhibitor, with radiation and gemcitabine resulted in better-than-expected overall survival in patients with locally advanced pancreatic cancer. The median overall survival was 22 months, surpassing previous results for the same treatment combination.
A University of Minnesota study found that high-fat foods significantly increase cannabidiol (CBD) absorption into the body. CBD exposure is vastly increased when taken with high fatty foods, and concentrations in the blood can be four times higher than fasting levels.
The study found that ERK was easily switched on in ancient one-celled creatures but carefully restrained as animals evolved. Researchers identified two key changes that likely brought ERK under more control across evolution.
A ketogenic diet has been shown to inhibit the growth of squamous cell carcinoma tumors in mice with lung cancer. The study also found a correlation between high blood glucose levels and poor survival among patients with squamous cell carcinoma.
The study examined 3,368 medical aid in dying prescriptions from Oregon (1998-2017) and Washington (2009-2017), finding that most patients were insured, non-Hispanic white individuals with cancer. The primary reasons for pursuing medical aid in dying were loss of autonomy, impaired quality of life, and loss of dignity.
Researchers develop innovative technology to transform proteins and antibodies into stable drug transporters, reducing side effects and increasing effectiveness in targeted cancer treatment. The new method allows for lower doses and fewer severe side effects compared to existing antibody-drug conjugates.
Researchers found that adding MS drug teriflunomide to targeted cancer therapy significantly shrinks glioblastoma tumors and improves mouse survival. The treatment targets cancer stem cells, which are responsible for tumor recurrence.
Researchers at Columbia University Irving Medical Center have identified a potential new therapy for pancreatic cancer. Their experimental compound, PTC596, has shown to be effective in combination with standard treatment, extending survival by three times in genetically engineered mice.
Researchers have identified a combination of gene mutations that are frequently found together in endometrial cancer and endometriosis-associated ovarian cancer. The ARID1A and PIK3CA genes' mutations can lead to uncontrolled cell growth, increasing the risk of cancer.
Researchers have identified a potential combination targeted therapy for a deadly type of leukemia found in some infants, which was linked to high levels of the BCL6 protein and poor outcomes. The therapy involves 'turning off' the BCL6 protein using ABT-199, promising a lifesaving treatment option for babies and young children.
Independent charity prescription drug assistance programs in the US primarily cover insured patients, leaving out those without health insurance. These programs tend to favor higher-priced brand-name drugs over generics.
Researchers used artificial intelligence to identify five new types of breast cancer with distinct patterns of response to treatment, including two that are more likely to benefit from immunotherapy. The study aims to personalize treatment for women with breast cancer by selecting patients for different drugs in clinical trials.
Biomedical researchers have created three-dimensional cell structures from diseased tissue of patients to study endometrial diseases like endometriosis and cancer. This new biobank can help unravel disorders and test drugs for effective treatments.
Researchers at Stanford University School of Medicine have discovered a new 'don't eat me' signal used by cancer cells to evade immune detection. Blocking this signal allows immune cells to attack and destroy cancer cells in mice implanted with human cancers, providing a potential basis for new anti-cancer therapies.
A phase-3 trial shows that combining rituximab with ibrutinib keeps patients disease-free for nearly three years and improves overall survival rates. The new treatment is more effective and better tolerated than traditional chemotherapy, revolutionizing the standard of care for chronic lymphocytic leukemia.
Researchers at the University of Birmingham have successfully extracted and modified a compound from feverfew to kill chronic lymphocytic leukemia cells in laboratory experiments. The compound, parthenolide, works by increasing reactive oxygen species levels in cancer cells, causing them to die.
The National Cancer Institute has recognized Sylvester Comprehensive Cancer Center as a top-tier US cancer center due to its outstanding research and clinical care. The designation is a testament to the dedication of every member of the cancer center.